hVIVO plc

Equities

HVO

GB00B6ZM0X53

Healthcare Facilities & Services

Delayed London S.E. Other stock markets			5-day change	1st Jan Change
- ^GBX	-.--%		+18.92%	+41.94%

Feb. 14	Hvivo Completes Secondary Placing	MT
Feb. 14	Hvivo Shareholders Plan Secondary Placing to Sell 14 Million Shares	MT

Hvivo : Recap on hVIVO scientific poster at ATS 2017, Washington D.C., May 2017

July 11, 2017 at 11:39 am EDT

July 11, 2017 4:32 pm

hVIVO's John Efthimiou, Executive Vice-President Translational Medicine R&D operations, presented a scientific poster at ATS 2017 in Washington, D.C. USA in May 2017.

Click here and complete your details to get access to this insightful hVIVO presentation, even if you didn't make it to the event in Washington, D.C. itself.

The hVIVO poster can still be viewed by following the link below:

'Differential White Blood Cell Changes During Human Rhinovirus (HRV) Induced Infection in Subjects with Asthma' John Efthimiou, Executive Vice-President Translational Medicine R&D operations, hVIVO.

Click here and complete your details to get access to this insightful hVIVO presentation to catch up on the latest from 'ATS 2017'!

hVIVO plc published this content on 11 July 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 11 July 2017 15:39:08 UTC.

Original documenthttp://hvivo.com/recap-hvivo-scientific-poster-ats-2017-washington-d-c-may-2017/

Public permalinkhttp://www.publicnow.com/view/0A6BF2C0F6E4EDD245406A8D332313A8ACDCE084

Latest news about hVIVO plc

Hvivo Completes Secondary Placing	Feb. 14	MT
Hvivo Shareholders Plan Secondary Placing to Sell 14 Million Shares	Feb. 14	MT
Hvivo Wins GBP6 Million Antiviral Testing Contract	Jan. 02	MT
Hvivo Secures GBP17 Million Contract for RSV Antiviral Drug Testing; Stock Surges	Dec. 13	MT
Earnings Flash (HVO.L) HVIVO Reports H1 Revenue GBP27.3M	23-09-12	MT
Earnings Flash (HVO.L) HVIVO Posts H1 EPS GBX0.58	23-09-12	MT
HVIVO Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-12	CI
Lab Services Company Hvivo to Build New London Facility	23-08-29	MT
HVIVO plc Plans for A New Facility to Meet Growing Demand	23-08-29	CI
Hvivo Wins GBP13 Million Contract from Global Pharma Client	23-07-25	MT
HVIVO Surges 10% on GBP7 Million RSV Drug Testing Contract With Asian Pacific Drugmaker	23-02-06	MT
UK's hVIVO Signs GBP2.5 Million Contract for RSV Vaccine Candidate Testing	23-01-04	MT
HVIVO Up 9% With $16 Million Antiviral Testing Contract	22-11-10	MT
HVIVO Announces £10.4 Million Contract with Existing Big Pharma Client	22-08-22	CI
Cocrystal Pharma Engages hVIVO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344	22-08-08	CI
HVIVO Limited Signs £6.2 Million Influenza Human Challenge Study Contract	22-08-04	CI
Hvivo Signs £7.2 Million Contract with an Existing Top 5 Global Pharmaceutical Company to Test Its Orally Administered Antiviral Product	22-06-14	CI
HVIVO Signs GBP 14.7 Million Influenza Contract	22-06-01	CI
HVIVO Signs a £7.3 Million Influenza Human Challenge Study Contract Win	22-05-18	CI
HVIVO Receives New Study with an Existing Big Pharma Client to Act as A Vaccination Site for A Phase II Field Study	22-05-05	CI
HVIVO Signs Substantial Contract with an Existing Top 5 Global Pharmaceutical Client to Manufacture Virus for Use in Human Challenge Studies	22-05-04	CI
HVIVO Wins £5 million RSV Human Challenge Study Contract	22-03-25	CI
HVIVO Announces Positive Results from RSV Human Challenge Study	22-02-17	CI
HVIVO Signs £5 Million Influenza Human Challenge Study Contract with a Biotech Company	21-12-21	CI
Hvivo Limited Signs $13.4 Million Contract with A US-Based Biotechnology Company to Test Its Novel Antiviral Candidate Using the Hvivo Influenza Human Challenge Study Model	21-12-10	CI

Chart hVIVO plc

Duration

Period

More charts

Company Profile

hVIVO plc, formerly Retroscreen Virology Group plc, is a holding company. The Company is engaged in a life sciences business pioneering a technology platform of human disease models to accelerate drug discovery and development in respiratory and infectious diseases, including flu, respiratory syncytial virus (RSV), asthma and common cold. It has commercialized approximately four disease models, enrolled over 2,000 subjects and conducted approximately 40 product validation studies for a range of industry, government and academic clients and collaborators. The Company offers services, such as challenge study services, lab services, and target and biomarker discovery. It offers viral challenge studies in healthy volunteers in influenza, human rhinovirus (HRV) and RSV. Its lab services include assay development, transfer and optimization across the immunological, molecular and cell-based assay platforms, including offering options in sample matrix testing and specialty biomarker assays.

Sector

Healthcare Facilities & Services

More about the company

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
HVIVO PLC	+41.94%	18.04M
CVS HEALTH CORPORATION	-12.66%	86.92B
HCA HEALTHCARE, INC.	+19.19%	85.34B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+12.75%	29.88B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-10.55%	17.1B
FRESENIUS SE & CO. KGAA	-6.70%	15.24B
QUEST DIAGNOSTICS INCORPORATED	-6.70%	14.29B
EUROFINS SCIENTIFIC SE	+1.15%	12.38B
PURE HEALTH HOLDING	-30.53%	12.1B
DAVITA INC.	+24.05%	11.4B

Other Healthcare Facilities & Services